KYORIN Pharmaceutical (4569) Q3 2025 earnings summary

Executive summary

• Net sales for the nine months ended December 31, 2024, were ¥89,286 million, up 2.3% year-over-year.

• Operating profit reached ¥5,391 million, an 8.1% increase compared to the same period last year.

• Profit attributable to owners of parent was ¥2,439 million, down 41.2% year-over-year.

• Comprehensive income for the period was ¥2,361 million, a 41.8% decrease year-over-year.

Financial highlights

• Basic earnings per share for the nine months was ¥42.46, compared to ¥72.32 in the prior year.

• Total assets as of December 31, 2024, were ¥190,492 million, up from ¥177,627 million as of March 31, 2024.

• Net assets stood at ¥130,073 million, slightly down from ¥130,735 million at the previous fiscal year-end.

• Equity ratio decreased to 68.3% from 73.6% as of March 31, 2024.

Outlook and guidance

• Full-year net sales forecast for the year ending March 31, 2025, is ¥123,400 million, up 3.2% year-over-year.

• Operating profit is projected at ¥6,500 million, a 4.3% increase year-over-year.

• Profit attributable to owners of parent is forecast at ¥5,000 million, down 8.7% year-over-year.

• Earnings per share for the full year are expected to be ¥87.03.

• No revisions to the dividend forecast; annual dividend per share is projected at ¥52.00.